{"disease":{"id":"active-ulcerative-colitis-uc","name":"active ulcerative colitis uc"},"drugs":{"marketed":[{"drug_id":"chembl-chembl3358920","indication_name":"moderately to severely active ulcerative colitis (UC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"ETRASIMOD","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Velsipity works by binding to and modulating the activity of certain immune cells in the body."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07535489","title":"Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":144,"lead_sponsor_name":"Nanjing Immunophage Biotech Co., Ltd","has_results":false},{"nct_id":"NCT06681389","title":"A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"NIBEC Co., Ltd.","has_results":false},{"nct_id":"NCT05786404","title":"Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}